Health Condition(s) or Problem(s) Studied : Patients with photoaging skin calcium hydroxylapatite, photoaging
Conditions
Interventions
Patients were injected with calcium hydroxyapatite for 1 session. Then they were instructed to follow up at 1, 3, 6, 9 and 12 months after treatment.
Experimental Device
Cacium hydroxyapatite injection
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
25 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Male or female Thai participants aged 25 - 60 years. 2. Volunteers who have photoaging skin evaluated by a dermatologic surgery specialist using the Glogau classification of photoaging at moderate or higher level.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women. 2. Participants with a history of platelet disorders, coagulation abnormalities, anemia, liver disease, malignancy, or immunodeficiency. 3. Participants who smoke or consume alcohol excessively. 4. Participants with dermatitis, wounds, or active facial skin infections. 5. Participants with a history of allergy to local anesthetics. 6. Participants who regularly take hormonal medications, injectable or oral contraceptives, or NSAIDs. 7. Participants taking medications that affect blood coagulation (e.g., aspirin, anticoagulants). 8. Participants who underwent facial lifting procedures (energy-based devices or thread lift) within 6 months before enrollment. 9. Participants who received facial filler injections within 6 months before enrollment. 10. Participants who received platelet-rich plasma (PRP) facial injections within 6 months before enrollment. 11. Participants who received facial botulinum toxin injections within 6 months before enrollment. 12. Participants who underwent collagen-stimulating facial lasers e.g., picosecond laser, erbium:YAG, Fractora, or E-matrix - within 6 months before enrollment. 13. Participants with a history of hypertrophic scars or keloids. 14. Participants diagnosed with psychiatric disorders by a psychiatrist. 15. Participants with a known allergy to calcium hydroxylapatite.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wrinkle depth Baseline, 1, 3, 6, 9 and 12 months Antera,Wrinkle indentation index Baseline, 1, 3, 6, 9 and 12 months Antera,Texture roughness Baseline, 1, 3, 6, 9 and 12 months Antera | — |
Secondary
| Measure | Time frame |
|---|---|
| Volume Change Baseline, 1, 3, 6, 9 and 12 months Vectra H2,Volume Change Baseline, 1, 3, 6, 9 and 12 months Quantificare,R0 Baseline, 1, 3, 6, 9 and 12 months Cutometer,R2 Baseline, 1, 3, 6, 9 and 12 months Cutometer,Hydration level Baseline, 1, 3, 6, 9 and 12 months Corneometer,Redness Baseline, 1, 3, 6, 9 and 12 months Mexameter,Pigmentation Baseline, 1, 3, 6, 9 and 12 months Mexameter,Individual typology angle Baseline, 1, 3, 6, 9 and 12 months Colorimeter,Sebum level Baseline, 1, 3, 6, 9 and 12 months Sebumeter,Safety Baseline, 1, 3, 6, 9 and 12 months Adverse event,Physician improvement scale Baseline, 1, 3, 6, 9 and 12 months percent improvement,Patient Improvement scale Baseline, 1, 3, 6, 9 and 12 months percent improvement,Pain score Treatment visit Visual analog scale | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Faculty of Medicine Siriraj Hospital
Outcome results
None listed